Our previous results showed that oligodendrocyte development is regulated by both nociceptin and its G-protein coupled receptor, the nociceptin/orphanin FQ receptor (NOR). The present in vitro and in vivo findings show that nociceptin plays a crucial conserved role regulating the levels of the glutamate/aspartate transporter GLAST/EAAT1 in both human and rodent brain astrocytes.
| I N TR ODU C TI ON
Nociceptin/orphanin FQ (nociceptin) is an endogenous heptadecapeptide generated by cleavage of its precursor protein pre-pronociceptin (Meunier et al., 1995) . Our previous findings suggested that nociceptin regulates oligodendrocyte development and may prevent precocious brain myelination (Eschenroeder, Vestal-Laborde, Sanchez, Robinson, & Sato-Bigbee, 2012 ). The present study provides evidence indicating that nociceptin also plays an important role in maturing rodent and human astrocytes, stimulating the expression of the glutamate transporter GLAST/EAAT1. Nociceptin binds to a G-protein coupled receptor known as the nociceptin receptor (NOR) or opioid receptor like-1 (ORL1), the most recently discovered member of the opioid receptor family. Interestingly, although nociceptin shows structural similarity to dynorphin A (Lapalu et al., 1997) , it does not bind to the classical l-, dor j-opioid receptors. Likewise, NOR shows no binding affinity for the classical endogenous opioids, including dynorphin A, b-endorphin, and enkephalin (Meunier et al., 1995; Reinscheid et al., 1995) . A number of roles for nociceptin and NOR in the central nervous system (CNS) have been investigated, the most well studied being pain modulation. The differing effects between supraspinal and spinal administration of nociceptin, hyperalgesia, and analgesia, respectively, make the nociceptin system a unique target among the opioid receptor family (Heinricher, McGaraughty, & Grandy, 1997; Pan, Hirakawa, & Fields, 2000; Rizzi et al., 2006) . NOR activation has also been shown to exert anxiolytic effects in different models of stress (Jenck et al., 2000; K€ oster et al., 1999) and NOR knockout mice exhibit increased learning ability, memory, and hippocampal long term potentiation (Mamiya, Noda, Nishi, Takeshima, & Nabeshima, 1998; Noda et al., 2000; Yu and Xie, 1998) .
Furthermore, NOR-deficient mice also develop altered responses to Glia. 2017; 65:2003 -2023 wileyonlinelibrary.com/journal/glia morphine (Chung, Pohl, Zeng, Civelli, & Reinscheid, 2006; Rizzi et al., 2000; Mamiya et al., 2001; Ueda, Inoue, Takeshima, & Iwasawa, 2000; Ueda et al., 1997) , nicotine (Sakoori and Murphy, 2009) , heroin (Kallupi et al., 2017) , ethanol (Kallupi et al., 2013) , and cocaine (Kallupi et al., 2017; Marquez, Hamid, & Lutfy, 2013; Marquez, Nguyen, Hamid, & Lutfy, 2008) , indicating a possible role of the nociceptin system in drug addiction.
Interestingly, early studies showed that the levels of prepronociceptin mRNA expression are significantly elevated during embryonic and early postnatal life (Ikeda et al., 1998) . However, little is known about the role of nociceptin in brain development. The present studies establish a role for this molecule in developing astrocytes. Once considered as simple support cells, research in the recent decades demonstrated that astrocytes are instead a complex cell population that plays a number of crucial roles; including among others being responsible for guiding neuronal migration (Komuro and Rakic, 1998; Rakic, 1995) , control of synapse number and maintenance (Ullian, Sapperstein, Christopherson, & Barres, 2001 ), regulation of neuronal activity (Halassa and Haydon, 2010), brain glycogen storage and energy production (Brown and Ransom, 2007; Pellerin and Magistretti, 1994) , water distribution (Nielsen et al., 1997) , antioxidant metabolism (Aschner, 2000) , ion buffering (Bevan, Chiu, Gray, & Ritchie, 1985; Bordey and Sontheimer, 2000) , and induction and maintenance of the blood brain barrier (Hawkins and Davis, 2005; Janzer and Raff, 1987) . However, one of the most critical roles played by astrocytes, both in the developing and the adult brain, is the regulation of neurotransmitter concentrations.
Because of its excitotoxic effects at high concentrations, excess glutamate is rapidly removed after synaptic transmission by a set of transport proteins expressed in astrocytes. The glutamate-aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1), respectively named EAAT1 and EAAT2 in humans, belong to the family of excitatory amino acid transporters (EAATs). Importantly, GLAST/EAAT1 is the main transporter during brain maturation and several lines of evidence indicate that GLAST/EAAT1 function during early brain development is fundamental beyond protection from glutamate-induced cytotoxicity and regulation of glutamatergic activity. This is because glutamate levels are known to regulate a variety of crucial developmental events that include among others, the proliferation and survival of neural progenitors (Brazel, Nuñez, Yang, & Levison, 2005; Jansson and Akerman, 2014; LoTurco, Owens, Heath, Davis, & Kriegstein, 1995; Luk, Kennedy, & Sadikot, 2003; Luk and Sadikot, 2004; Mattson, 2008; Zafra, Castr en, Thoenen, & Lindholm, 1991) , neuronal migration (Behar et al., 1999; Rakic, 1993, 1998) , and dendritic outgrowth (Jansson et al., 2013; Mattson, Dou, & Kater, 1988; Voss, Milne, Sharkey, O'Neill, & McCulloch, 2007; Whitney et al., 2008) . The critical developmental role of glutamate transporters is further evidenced by the observation that GLT-1/GLAST double knockout mice exhibit gross malformation of the brain due to incorrect migration and maturation of neurons as well as differentiation of astrocytes (Matsugami et al., 2006 
| Human and rat astrocyte cultures
Human cortical astrocytes prepared from fetal brain tissue provided by Advanced Bioscience Resources (Rockville, MD) were cultured as previously described (Kordula et al., 1998 
| In vivo administration of NOR inhibitor
Sprague-Dawley rats were injected intraperitoneally with BAN-ORL24 in phosphate-buffered saline (PBS) at a dose of 1 mg kg 21 day 21 on two different timelines as indicated in Figure 9 . Pups were administered the NOR inhibitor from PD3 to PD9 (Group 1) or PD9 to PD14 (Group 2). All controls were similarly injected with vehicle alone. At the end of the respective time periods, the rats were anesthetized with isofluorane and sacrificed. The brains were harvested, flash frozen on dry ice and kept at 2808C until use.
| Immunoblotting
Western blot analyses were done as described previously (Eschenroeder et al., 2012; Sanchez, Bigbee, Fobbs, Robinson, & Sato-Bigbee, 2008 showed no signal when the sample is observed in the green channel.
| Fluorescent in situ hybridization for NOR mRNA
In situ hybridization was performed by modification of a previously published protocol (Wang, Wang, Zhu, Cao, & Wu, 2000) . digoxigenin tag, were synthesized and purified by IDT. These sequences correspond to the rat and mouse/human NOR extracellular region located between transmembrane domains 4 and 5. Hybridization was done using 1 ng lL 21 of digoxigenin labeled-oligonucleotide probe in hybridization buffer at 378C for 18 hr. After hybridization, samples were washed twice with 50% formamide/5xSSC at 378C for 10 min, then once with 2xSSC at 378 for 10 min, once with 2xSSC at RT for 10 min, twice in 0.2xSSC at RT for 10 min, and finally rinsed three times in PBS at RT for 5 min.
The samples then underwent immunohistochemical detection of ALDH1L1 and digoxigenin, as previously described with minor modifications. Samples were then consecutively incubated for 1 hr at RT with blocking buffer (5% NGS and 0.1% Triton X-100 in PBS), and for 2 hr with a mixture of mouse anti-digoxigenin (5 lg mL
21
) and anti-ALDH1L1 (1:1,000) antibodies in blocking buffer. After rinsing in PBS, samples were reblocked for 20 min before the appropriate fluorescently conjugated secondary antibodies were added for 2hr at RT, then extensively rinsed with PBS and finally mounted with DAPI-containing Vectashield.
| Aspartate uptake assay
Aspartate uptake assay was carried out using a modification of previously published protocols (Escartin et al., 2011; Matos, Augusto, Oliveira, & Agostinho, 2008) . Cells were pre-incubated for 24 hrs in CDM alone, CDM with 1 lM nociceptin, CDM with 100 nM BAN-ORL24, or CDM with 100 nM BAN-ORL24 and 1 lM nociceptin. The cells were then pretreated for 10 min before the start of the uptake assay with CDM alone, CDM with 300 lM DHK or CDM with 1 lM TFB-TBOA.
The different groups of cells were then incubated in BSS-P (140 mM NaCl, 5 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgSO 4 , 0.5 mM KH 2 PO 4 , 5 mM glucose, 5 mM PIPES, pH 7.2) containing 0.5lCi of 3 H-D-aspartic acid and 100 lM non-radioactive D-aspartic acid for different times at 378C under 5% CO 2 . At the end of the incubation, the culture plates were placed on ice and carefully rinsed three times in ice-cold BSS-P.
Cells were then lysed with 200 lL 0.5N NaOH and aliquots used for measurement of radioactivity by liquid scintillation counting and protein determination by the Bradford assay (Bio-Rad).
| NOR knockout mice
The NOR knockout (KO) mice were raised in the laboratory of Dr. 
| Statistical analysis
Statistical analysis was performed by the nonparametric tests MannWhitney (for two group comparisons) or one-way analysis of variance on ranks (Kruskal-Wallis test) when comparing more than two experimental groups. All analyses were carried out using the GraphPad Prism program (La Jolla, CA). Differences were considered statistically significant when p values were <0.05.
| R E SU LTS

| Postnatal rat brain maturation is accompanied by a progressive decrease in nociceptin expression
Our previous findings suggested a role for nociceptin in oligodendrocyte maturation and early myelination (Eschenroeder et al., 2012) . Further support for the involvement of nociceptin in brain development is the observation that mRNA levels encoding prepronociceptin, the precursor of nociceptin, are higher in the immature than in the adult rodent brain (Ikeda et al., 1998; Neal, Akil, & Watson, 2001) . Moreover, our analysis of nociceptin protein levels in cerebral hemispheres from rat pups, revealed the highest expression between postnatal days 2 and 5, with peak values of 797.2 6 34.3 and 936.0 6 113.5 fmol lg 21 of protein, respectively (Figure 1) . However, the expression of this molecule gradually decreases, reaching values at 21 days after birth that are about six-fold lower than those observed in the 5-day-old pups.
Interestingly, the highest levels of postnatal nociceptin expression overlap with the peak of astrocyte development that is observed in rodents between 3 and 5 days of age (Mission, Takahashi, & Caviness, 1991) , raising the possibility that the nociceptin system may play a role in astrocyte maturation.
| Nociceptin and NOR expression in developing rodent and human astrocytes
Previous findings indicated the presence of both NOR protein and mRNA in cultured astrocytes from rat spinal cord (Fu, Zhu, Wang, & Wu, 2007) . Support for a role of nociceptin in developing brain astrocytes, was next provided by immunocytochemical staining of rat brains at postnatal day 5 (PD5), a timing that corresponds to the third trimester of CNS development in utero for humans (Figure 2 ). In these studies 3.3 | The nociceptin system regulates GLAST expression in rat and human developing astrocytes As depicted in Figure 6 , western blot analysis showed that incubation of the rat astrocytes in the presence of increasing concentrations of nociceptin did not affect expression of the cytoskeletal astroglial marker GFAP (Figure 6a ), but unexpectedly resulted in a dosedependent increase in the levels of the glutamate transporter GLAST (Figure 6b ). Important to note is that these cultures exhibit a high molecular weight form of GLAST that has been previously shown (Schlag et al., 1998; Ye and Sontheimer, 2002) to be characteristic of immature astrocytes. Others have demonstrated that the "classical" low molecular weight GLAST is on the other hand the predominant form that is expressed when the maturation of astrocytes is induced by treatment with dibutyryl cAMP (Carbone, Duty, & Rattray, 2012; Duan, Anderson, Stein, & Swanson, 1999; Filosa et al., 2009; Schlag et al., 1998; Susarla et al., 2004) . Importantly, an interesting developmental expression pattern of these GLAST bands is observed in vivo.
As shown in Figure 6c , western blot of total brain homogenates reveals that the higher molecular weight form of GLAST predominates before PD9, an age at which the high and low molecular weight bands appear (g-i) Cortical brain slices were subjected to immunohistochemical staining with (g) anti-ALDH1L1 antibody and to in situ hybridization using (h) a digoxigenin-labeled probe for NOR mRNA, as indicated under "Methods". Notice the presence of nociceptin (c), NOR protein (f) and NOR mRNA in the ALDH1L1-labeled astrocytes (i). Nuclei were counterstained with DAPI. Scale bar: 10 lm. Controls for immunocytochemistry using the appropriate normal sera as well as in situ hybridization controls using nonsense deoxyoligonucleotide probes are shown in Supporting Information Figures 1 and 2 , respectively to be present in equivalent amounts. However, after this time, the low molecular weight band, believed to be the monomeric form of GLAST, is more prominent.
To further substantiate the specificity of nociceptin action, the cells were then cultured in CDM alone, CDM with 1lM nociceptin, CDM with 100nM NOR inhibitor BAN-ORL24 (NOR-I), or CDM supplemented with a combination of both nociceptin and NOR-I ( Figure   6d ). As described above, a 24-hr incubation with nociceptin resulted in a significant elevation in GLAST expression. However, this effect was abrogated upon coincubation with NOR-I, indicating that activation of NOR is a necessary step in the nociceptin-dependent upregulation of GLAST. Interestingly, Figure 6d also shows that NOR-I treatment itself causes a small but statistically significant decrease in GLAST levels.
Because no effects on cell viability were detected, this could be attributed to an inhibitory effect on the action of endogenously produced nociceptin. This possibility is supported by the observation that as already indicated above (Figures 2, 3 , and 5), both rat and human in vivo and cultured astrocytes express nociceptin. Furthermore, as 
| The nociceptin system regulates GLAST activity
Importantly, the elevation of GLAST protein levels induced by nociceptin is indeed accompanied by an increase in transporter activity. As depicted in Figure 8a , cells exhibited increased aspartate uptake when transporter activity was assayed after a 24 hr pretreatment with nociceptin. This uptake was not affected by treatment with the GLT-1 selective inhibitor DHK, but was in contrast reduced to background levels by the GLT-1/GLAST inhibitor TFB-TBOA (Figure 8b ). These observations indicate that the nociceptin-induced increase in aspartate transport is indeed mediated by GLAST. Treatment of astrocytes with nociceptin results in a dose-dependent increase in GLAST expression. Astrocytes isolated from 3-day-old rat brains were treated for 24 hr with increasing concentrations of nociceptin. (a) GFAP and (b) GLAST expression were evaluated by western blot analysis, using b-actin as loading control. Results are expressed as change relative to control values and represent the mean 6 SEM, n 5 3, *p < 0.05, **p < 0.01, ***p < 0.001. (c) GLAST levels in total brain homogenates from 2-, 5-, 9-, 13-, 18-, and 21-day-old rats were determined using western blot. Each gel lane was loaded with 5 lg of protein and levels for the 60 kDa (black bars) and 120 kDa (open bars) molecular forms of GLAST correspond to the mean 6 SEM from three animals per age. (1) cells/field. Results are the mean 6 SEM from three independent experiments in which ten fields/well, three wells/condition, containing 100 cells per field were analyzed, control vs. nociceptin, *** p < 0.001 these effects may be part of an autocrine loop that contributes to glutamate homeostasis in the developing brain.
| In vivo regulation of GLAST expression by the nociceptin system
The results described above raised the question of whether nociceptin effects on GLAST expression are also observed in vivo. To investigate this problem, we focused on the first 2 weeks of life which not only
show the highest levels of postnatal nociceptin expression, as already indicated in Figure 1 , but also represent a major time period of astrocyte proliferation and differentiation in rodents (Mission et al., 1991; Rice and Barone, 2000) . To evaluate the role of nociceptin in vivo, rat pups were administered the blood-brain barrier permeable NOR-I, BAN-ORL24 (1 mg kg 21 day
21
), using two separate schedules ( Figure   9a ). In the first group, pups received daily injections from PD3 to PD9, a time period that includes the peak of both astrocyte development and postnatal nociceptin expression. A second group of animals was administered the NOR-I from PD9 to PD14, a window that does not include the peak of astroglial development but encompasses other
FIG URE 8
3 H-aspartate uptake increases in primary rat astrocytes treated with nociceptin. (a) Aspartate uptake in primary rat astrocytes after 24-hr preincubation in CDM alone (controls, open bars) or CDM with 1 lM nociceptin (black bars) was determined using a 3 H-D-aspartate uptake assay, as described under Methods. Results expressed as pmol/lg protein/min and are the mean 6 SEM from at least 10 replicates/condition, *p < 0.05, ***p < 0.001. (b) Aspartate uptake was assessed in cell cultures after 24 hr pretreatment in CDM alone (white bars) or CDM supplemented with 1 lM nociceptin (black bars). Prior to the assay, parallel controls and nociceptin-treated cultures were in addition pre-incubated for 10 min with either 300 lM DHK or 1 lM TFB-TBOA. Results are expressed as change in uptake over 30 min and represent the mean 6 SEM from at least six replicates/condition, control vs. control with TFB-TBOA and nociceptin vs. nociceptin with TFB-TBOA, ***p < 0.0001. (c) Aspartate uptake was assessed in primary rat cultures treated for 24 hr with CDM alone (control), or CDM supplemented with either 100 nM NOR-I, 1 lM nociceptin, or 1 lM nociceptin with 100 nM NOR-I. Results are expressed as change in uptake over 30 min and represent the mean 6 SEM from at least six replicates/condition. Control vs. NOR-I, **p < 0.01; control vs. nociceptin, ***p < 0.001; nociceptin vs. nociceptin with NOR-I, ***p < 0.001. Arrow 1: aspartate uptake due to endogenously produced nociceptin. Arrow 2: aspartate uptake due to exogenously added nociceptin
In vivo treatment with an NOR inhibitor or genetic ablation of NOR affect GLAST brain expression. (a) Rat pups were given daily IP injections of BAN-ORL24 (NOR-I) on two different timelines: from postnatal day 3 to 9, or postnatal day 9 to 14. Total homogenates prepared from brains collected at the end of each timeline were subjected to western blot analysis for GLAST and GLT-1. (b and c) GLAST expression in total brain homogenates of animals injected from (b) postnatal day 3 to 9 and (c) postnatal day 9 to 14. (d and e) GLT-1 levels in brain homogenates from pups injected from (d) postnatal day 3 to 9 and (e) postnatal day 9 to 14. The results are expressed as change relative to control values and represent the mean 6 SEM from at least five animals. **p < 0.01; n.s., not significant; ND, not detected. (F) 5-day-old WT and NOR KO mouse cortical brain tissue slices were subjected to immunohistochemical staining with (a and d) anti-ALDH1L1 antibody and in situ hybridization using (b and e) a digoxigeninlabeled probe for NOR mRNA, as indicated under "Methods." Notice the presence of NOR mRNA in ALDH1L1-labeled astrocytes in WT mice (a-c) and lack of NOR mRNA in the NOR KO animals (d-f). Scale bar: 10 lm. (g and h) Total brain homogenates from 14-day-old WT and NOR knockout mice were subjected to western blot analysis to evaluate expression of (g) GLAST and (h) GLT-1, using b-actin as loading control. Results are represented as change relative to WT and are the mean 6 SEM from four animals, * p < 0.01 events such as the start of myelination. Comparison with vehicleinjected control pups, indicated that GLAST expression was significantly decreased in the brains of animals treated with NOR-I from PD3
to PD9 (Figure 9b ). However, no significant differences between controls and NOR-I-treated rats were detected when the inhibitor was administered between PD9 to PD14 (Figure 9c ). Altogether, these results point to a role of the nociceptin system that is restricted to the first 9-10 days of postnatal rat brain development. In contrast, no effects of NOR-I were detected when the same animals were examined for the brain expression of GLT-1 (Figure 9d,e) . Notice that only background levels of GLT-1 are observed at PD9 (Figure 9d ) as the expression of this glutamate transporter is known to begin after the first postnatal week (Schreiner et al., 2014; Ullensvang, Lehre, StormMathisen, & Danbolt, 1997) .
To further substantiate these observations we determined GLAST levels in wild-type (WT) and NOR KO mice. Analogous to the rat and human cells, mouse astrocytes also express NOR mRNA ( Figure 9F ,ac), which is clearly absent in the NOR KO animals ( Figure 9F ,d-f). In these animals, a role of the nociceptin system in controlling GLAST expression is further supported by the observation that NOR KO mice exhibit decreased GLAST brain levels ( Figure 9g ). Furthermore, similar to the observations on GLT-1 expression in the NOR-I injected pups (Figure 9d,e) , the unaffected GLT-1 levels in NOR KO animals ( Figure   9h ), supports the notion that nociceptin effects are restricted to GLAST expression. There is a possibility that changes in GLAST expression in these experiments may be due to unpredicted effects of nociceptin on astrocyte proliferation. However, cultured astrocytes treated with either nociceptin or NOR-I did not display differences in Ki-67 levels, a marker of proliferation (data not shown). Altogether, these results further substantiate the notion that nociceptin signaling plays a crucial role in controlling GLAST expression in developing astrocytes.
3.6 | The stimulation of GLAST expression by nociceptin involves a PI-3K/AKT, mTOR, and JAKmediated pathway
We next thought to investigate the molecular mechanisms that regulate GLAST expression downstream of NOR activation. Testing of a number of specific enzyme inhibitors (data not shown) determined that neither ERK, PKA, PKC, p38MAPK, CamKII, nor adenylate cyclase play any significant role in the nociceptin-dependent up-regulation of GLAST. However, significant results were obtained when investigating the role of a PI-3K/AKT-dependent pathway. In these studies, cells were pre-incubated for 2 hr in DMEM-F12 medium alone to downregulate potential previous signaling induced by endogenously produced nociceptin. As shown in Figure 10a , incubation in CDM alone elicits Furthermore, the role of a PI-3K/AKT pathway downstream of NOR activation is substantiated by the finding that PI-3K inhibition indeed blocks the capacity of nociceptin to increase GLAST expression, as
shown by both immunocytochemical staining ( Figure 10b ) and western blot analysis (Figure 10c ) of the cells. In addition, as shown in Figure   11 , the stimulatory effect of nociceptin is also blocked by rapamycin, an inhibitor of the mTOR kinase complex that is a key regulator frequently downstream of PI-3K/AKT activation. Treatment with rapamycin abolishes the capacity of nociceptin to increase both the percentage of astrocytes expressing GLAST (Figure 11a ) as well as the elevation of GLAST levels detected by western blotting (Figure 11b ).
Furthermore, the stimulatory effect of nociceptin on GLAST expression was also blocked by the Janus kinase (JAK) inhibitor I (Figure 11a,b) .
Moreover, this inhibitor also blocks the sustained nociceptindependent stimulation of AKT phosphorylation observed at 60 min (Figure 11c ), suggesting that JAK acts upstream of PI-3K. This is particularly interesting as a JAK/STAT pathway was implicated in regulating
GLAST expression in a model of perinatal hypoxia (Raymond, Li, Mangin, Huntsman, & Gallo, 2011) . Furthermore, JAK/STAT signaling is believed to control the differentiation of nestin (1) 
| D I SCUSSION
The studies undertaken in this investigation uncovered a novel role for the nociceptin system during brain maturation. Our in vitro and in vivo findings showed that nociceptin plays a conserved role stimulating the expression of the glutamate transporter GLAST/EAAT1 in both rodent and human developing astrocytes. This regulatory effect is mediated by NOR and the downstream participation of a complex signaling cascade that involves the interaction of several kinase systems, including PI-3K/AKT, mTOR, and JAK. The observation that the cells produce and secrete nociceptin suggests the existence of a nociceptin-mediated autocrine loop crucial to the regulation GLAST expression and glutamate homeostasis in developing astrocytes. Previous studies (Saito, Maruyama, Saido, & Kawashima, 1997; Zaveri et al., 2006) showed that nociceptin can influence neuronal differentiation and neurite outgrowth; and findings from our laboratory suggested a role of this peptide in oligodendrocyte development (Eschenroeder et al., 2012) . The present results further implicate the nociceptin system as a critical regulatory player during CNS formation and brain maturation.
An important observation of these studies is the specificity of timing for these nociceptin effects. The in vivo findings indicate that, overlapping with the temporal elevation of nociceptin brain concentration and astroglial NOR expression, the capacity of nociceptin to increase GLAST levels in the rat brain is restricted to a developmental window that encompasses the first 9-10 days of life. This observation is particularly significant because this postnatal period in rodents, equivalent to the third trimester in humans (Workman, Charvet, Clancy, Darlington, & Finlay, 2013) , is known to be representative of a timing at which a major number of glutamatergic synapses is formed in the mammalian brain. Importantly, this crucial developmental event immediately follows the rapid generation of astrocytes (Miller and Gauthier, 2007 ) and occurs at a time at which astrocytic GLAST/EAAT1 is still the dominant transporter responsible for local control of glutamate levels (Danbolt, 2001 ). This early GLAST/EAAT1 function is fundamental beyond protection from glutamate-induced cytotoxicity and regulation of glutamatergic activity, as results from different laboratories have pointed to glutamate as a pivotal regulator of crucial aspects of brain maturation.
Glutamate has been shown to control the proliferation and survival of neural progenitors (Brazel et al., 2005; LoTurco et al., 1995) and to stimulate the rate of neuronal migration (Behar et al., 1999; Rakic, 1993, 1998) . Activation of glutamate receptors by subtoxic levels can also result in opening of voltage-dependent Ca 21 channels, with subsequent suppression of growth cone function and dendritic outgrowth (Mattson et al., 1988) ; and both metabotropic and ionotropic glutamate receptors are thought to play an important role in the cell contact-mediated suppression of sprouting that occurs prior to the establishment of action potential activity (Miskevich, Lu, Lin, & Constantine-Paton, 2002) . Direct activation of NMDA, AMPA and KA receptors by glutamate increases both branching and length of process outgrowth (Jansson et al., 2013; Komuro and Rakic, 1993; Voss et al., 2007; Whitney et al., 2008) , and studies from Kwon and Sabatini (Kwon and Sabatini, 2011) showed that glutamate is also able to induce the de novo growth of functional spines in the developing cortex. In addition, glutamate signaling was shown to directly control transcription factor activation in developing oligodendrocytes (Pende et al., 1997; Sato-Bigbee, Pal, & Chu, 1999) . Importantly, these multiple glutamate effects are concentration-dependent, underscoring the role of nociceptin as a regulator of astrocytic GLAST/EAAT1 expression and the potential importance of this function in brain development. This raises the question of whether alterations in nociceptin system activity may disrupt glutamate-dependent steps during brain maturation, in particular those that could result in abnormal synapse plasticity and connectivity. In support of this possibility, studies have shown that NOR knockout animals exhibit a variety of abnormal responses; including those involved in spatial memory and learning (Noda et al., 2000) , feeding behavior and neuronal excitability (Farhang, Pietruszewski, Lutfy, & Wagner, 2010; Koizumi, Cagniard, & Murphy, 2009 ) as well as responses to drug effects (Chung et al., 2006; Kallupi et al., 2013 Kallupi et al., , 2017 Mamiya et al., 2001; Marquez et al., 2008 Marquez et al., , 2013 Rizzi et al., 2000; Murphy, 2004, 2009; Ueda et al., 2000) . It remains to be determined whether such findings could be solely explained by direct effects of nociceptin on neuronal cells, or might also reflect among other possibilities, an underlying alteration in network connectivity resulting from early defects in glutamate homeostasis and brain development.
While the present observations indicate that the effects of nociceptin on astroglial GLAST/EAAT1 expression are restricted to a specific window of early brain development, different reports raise the question of whether nociceptin plays a similar role at a later time under pathological conditions. Such may be the case of epilepsy, a disease characterized by the presence of elevated levels of extracellular glutamate (Cavus et al., 2005 ). An intriguing outcome from studies using the kainic acid model of epilepsy, is the presence of abnormally elevated levels of nociceptin (Aparicio et al., 2004; Bayrakdar et al., 2013; Bregola, Candeletti, Romualdi, & Simonato, 1999 , 2002b followed in time by upregulation of GLAST expression (Nonaka et al., 1998) . However, the possibility of a positive role of nociceptin in controlling GLAST levels in epilepsy is difficult to assess at this time as studies in animal models have indicated contradictory results pointing to both protective (Bayrakdar et al., 2013; Carmona-Aparicio, Peña, Borsodi, & Rocha, 2007 ; Guti errez, Leff, Romo-Parra, Acevedo, & Ant on, 2001) as well as permissive (Aparicio et al., 2004; Binaschi et al., 2003; Bregola et al., 2002a,b) roles of the nociceptin system in this disease. Nevertheless, one could argue that the increase in nociceptin levels in epileptic subjects could result in a compensatory rise in the level of GLAST to protect the brain from further excitotoxic effects of glutamate.
The present results also further emphasize the developmental differences between GLAST/EAAT1 and GLT-1/EAAT2. In agreement with the observations from other laboratories (Schreiner et al., 2014; Ullensvang et al., 1997) , we were unable to detect in the current study GLT-1 expression in the younger group of pups (postnatal days 3 to 9).
Interestingly, while GLT-1 is readily detectable in the brain of older animals, no significant differences in GLT-1 expression were observed at any age group between controls and NOR inhibitor-treated rats or between wild-type and NOR KO mice, indicating that, in contrast with GLAST, GLT-1 is not regulated by the nociceptin system. These findings add to results from others demonstrating that GLAST and GLT-1, which have almost equal affinities for glutamate and similar structures, are on the other hand differentially regulated and maintain unique Danbolt, 2001; Furuta, Rothstein, & Martin, 1997; Gegelashvili, Dehnes, Danbolt, & Schousboe, 2000; Mim, Balani, Rauen, & Grewer, 2005; Perego et al., 2000; Rothstein et al., 1996; Schlag et al., 1998; Schreiner et al., 2014; Ullensvang et al., 1997; Wadiche, Arriza, Amara, & Kavanaugh, 1995) .
Interestingly, nociceptin may also regulate GLAST levels in another glial cell type, GLAST is also expressed in oligodendrocytes and their precursors (DeSilva, Kabakov, Goldhoff, Volpe, & Rosenberg, 2009; Domercq and Matute, 1999; Pitt, Nagelmeier, Wilson, & Raine, 2003) .
The present findings in astrocytes, together with our previous results indicating the presence of NOR in developing oligodendrocytes (Eschenroeder et al., 2012) , raise the possibility that nociceptin may also play a role regulating GLAST expression in these glial cells. Fur- Carmen Sato-Bigbee http://orcid.org/0000-0002-3619-800X
